Safety & evidence

BPC-157
side effects

What regulators and studies have recorded about BPC-157 side effects, what nobody has measured, and what the cancer question rests on, as of November 2026.

Short answerSafety & evidence · 6 min read · Updated 18 Nov 2026

BPC-157’s side effects in people have not been characterised. Briefing a July 2026 advisory committee, FDA staff found five small, short human studies and three adverse-event reports, judged one reaction likely due to a product that also contained TB-500, and called it unclear whether the three were attributable to BPC-157. They found no carcinogenicity study and wrote that injected BPC-157 “may pose a significant risk for immunogenicity”.

Key takeaways

  • In July 2026, FDA staff concluded there is insufficient clinical safety information to characterise BPC-157’s safety profile, and that given by injection or nasally it “may pose a significant risk for immunogenicity”.
  • The five human studies FDA reviewed were small and short: no serious adverse events appear to have been reported, but safety data were limited and monitoring mostly unclear.
  • FDA’s database held three adverse-event reports to December 2025; FDA judged one reaction likely due to a product containing BPC-157 and TB-500, but could not assess BPC-157’s role.
  • FDA identified no carcinogenicity study. Cell and rodent papers report new blood-vessel growth; researchers disagree about what that means for cancer, and there are no human data.
  • Most certificates of analysis for BPC-157 that FDA staff found in the literature reported only a purity result.

01BPC-157 side effects at a glance

What regulators and studies have recorded, dated 18 November 2026.

QuestionWhat is recorded
Is there a side-effect profile for people?No. FDA staff, July 2026: “There is insufficient clinical safety information to characterize the safety profile” of BPC-157.
Human studies FDA reviewedFive, all small and short. No serious adverse events “appear to have been reported”, but the authors “provided limited information on safety data”, and safety monitoring for most “is unclear”.
Most frequent adverse events in a studyHeadache and flatulence, in FDA’s summary of meeting abstracts on one healthy-volunteer study.
FDA adverse-event reports, to 4 Dec 2025Three, all involving injectable products. FDA judged one reaction “likely due to the drug product”, which also contained TB-500, but could not assess BPC-157’s role; of all three, “it is unclear whether these AEs were attributable to BPC-157.”
FDA food and supplement complaints, to 3 Dec 2025Three, each complicated by a multi-ingredient dietary supplement, other medicines or missing details.
Published case reportsNone identified by FDA staff in their 2026 review. One has appeared since: a 2026 report of three dental patients given several agents at once, without a control group.
Animal toxicologyOne 2020 paper with 28-day studies in rats and dogs. FDA staff note signals in clotting tests and liver-related blood values, and no longer studies.
Immune reactionsFDA staff, 2026: given by injection or nasally, BPC-157 “may pose a significant risk for immunogenicity”, the tendency to provoke an immune response. They found no study that formally investigated it.
Cancer studiesFDA identified no carcinogenicity study. No human data.
Long-term human safetyUnknown. We found no published long-term human study (PubMed, November 2026).

02What side effects were recorded in human studies of BPC-157?

In a July 2026 briefing for its Pharmacy Compounding Advisory Committee, FDA staff reviewed the five clinical studies they found. No serious adverse events appear to have been reported, they wrote, but the studies “were of short duration, had small sample sizes”, and the authors “provided limited information on safety data”. Safety monitoring for most of them “is unclear”. In FDA’s summary of meeting abstracts on one healthy-volunteer study, the most frequently reported adverse events were headache and flatulence.

Both halves matter. A short study in a few dozen people can show that common, immediate problems were not obvious. It cannot show that uncommon or delayed ones do not happen (why: are peptides safe?). Every study we found that gave BPC-157 to people, with its design and size: BPC-157 human studies.

03What adverse-event reports exist for BPC-157?

FDA’s adverse-event database (FAERS, since renamed the FDA Adverse Event Monitoring System) held three BPC-157 reports up to 4 December 2025, all involving injectable products. One was redness and swelling around the injection site in a woman who was also using compounded thymosin, which FDA says limits interpretation. One was shortness of breath leading to an emergency-room visit, with no further information. The third was darkening of the skin and gums in a woman using a product labelled for research purposes that contained BPC-157 and TB-500; the reaction returned when she used it again. FDA staff judged that reaction “likely due to the drug product” but, because the product contained two peptides, could not assess whether BPC-157 played a role. Of all three, FDA wrote that “it is unclear whether these AEs were attributable to BPC-157”.

FDA’s complaint system for foods, supplements and cosmetics held three more cases, each complicated by BPC-157’s use in a multi-ingredient dietary supplement, other medicines or missing details. FDA staff found no published case report about BPC-157; one has appeared since, a 2026 report of three patients given several agents at once.

None of this gives a rate. FDA notes there is “no certainty that the reported adverse event was due to the suspect product”, that it does not receive every report, and that pharmacies compounding under section 503A generally do not report adverse events to it.

In Australia, Victoria’s Chief Health Officer reported 13 cases of anaphylaxis linked to unapproved peptides, notified since July 2025, in an advisory dated 27 October 2026. The advisory names no substance, and BPC-157 does not appear in it. Australia’s TGA lists adverse events it has received for unapproved peptide products, including severe allergic reactions requiring adrenaline and hospitalisation, without saying which products were involved (advisory of 13 April 2026). If you have had a reaction to any product: how to report it. How to weigh reports like these: peptide side effects, documented and unknown.

04Is there evidence linking BPC-157 to cancer?

No human data exist either way. What exists is a gap in standard testing and an argument built on blood-vessel studies in cells and animals.

EvidenceWhat it showsWhat it can’t show
Genetic-toxicity tests in one 2020 paper: bacteria, hamster cells, mouse bone marrow (T4/T3)Summarising the paper, FDA staff wrote that the results “demonstrate that BPC-157 is not a mutagen”: these tests found no increase in gene mutations or chromosome damage.Whether it affects tumours. FDA identified no carcinogenicity study, the kind of animal study used to assess cancer risk.
Blood-vessel studies in chick embryos, human endothelial cells and rats (Hsieh 2017; T4/T3)Researchers report that BPC-157 increased new blood-vessel growth (angiogenesis) and the expression of the VEGFR2 receptor.Whether this happens in people, or near a tumour.
PeopleNo study of cancer in people. We found no case report linking BPC-157 to cancer (PubMed, 18 Nov 2026).Delayed effects. We found no long-term human study (PubMed, November 2026), and FDA does not receive every adverse-event report.

Why the question comes up. A 2025 review by researchers in Warsaw and Gdańsk (Józwiak et al.) noted that tumours rely on new blood vessels, that the VEGF family and its receptors are expressed in about half of the human cancers studied, and predicted that BPC-157’s stimulation of blood-vessel growth is “likely to have some undesirable consequences”. A 2026 clinical review in Missouri Medicine lists “theoretical tumor neovascularization/metastasis” among BPC-157’s risks. Researchers at the University of Zagreb, where FDA staff say BPC-157 was first synthesised, replied in 2025 that the concern is “speculation”, arguing from their own animal and cell studies that BPC-157 “controls angiogenesis”.

Both sides argue from preclinical data. Neither has data in people. FDA staff add that BPC-157’s molecular targets “have not been identified”, which makes any of these mechanisms hard to judge. The mechanisms proposed so far: BPC-157 research guide.

05Is the risk in the molecule or the vial?

For products sold outside the medical system, what is in the vial is a separate risk from the molecule. In its 2026 review, FDA staff found that most certificates of analysis for BPC-157 in the literature reported only a purity result. FDA’s compounding page says compounded drugs containing it “may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization”, and that the agency “lacks sufficient information to know whether the drug would cause harm when administered to humans”. The 2026 briefing is stronger: given by injection or nasally, BPC-157 “may pose a significant risk for immunogenicity, potentially amplified by aggregation as well as potential peptide-related impurities”.

Australia’s TGA names BPC-157 among its examples of unapproved peptide products and says these products “have not been assessed by the TGA for safety, quality or effectiveness”, listing what they actually contain among the information that remains unknown (advisory of 13 April 2026).

We found no peer-reviewed independent survey of the quality of research-labelled BPC-157 (PubMed, 18 November 2026). What has been documented for other peptides: fake and contaminated peptides. How to check a lab report line by line: how to read a COA.

06What we don’t know about BPC-157 side effects

  • Its side-effect profile in people. FDA staff found too little clinical safety information to characterise it.
  • Long-term safety. We found no published long-term human study (PubMed, November 2026), and a 2026 orthopaedic review concluded that validated pharmacokinetic and long-term safety data for BPC-157 are lacking.
  • Cancer risk. FDA identified no carcinogenicity study, and there are no human data.
  • How often uncommon reactions occur. The human studies were too small, and spontaneous reports cannot give a rate.
  • Whether a given reaction came from BPC-157 or from the product: another peptide, an impurity or the wrong substance.

Suspected reaction to any product? Seek medical care first, then report it: how to report a reaction in the US, UK or Australia. For anything about your health, a doctor who knows you is the right call.

This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not medical advice.

RefSources

  1. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: BPC-157-related bulk drug substances. Advisory committee briefing, 2026 (pp. 14–15, 19, 32, 34–47); read 18 Nov 2026. www.fda.gov/media/193343/download
  2. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Web page, content current as of 22 Apr 2026; read 18 Nov 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-s…
  3. Department of Health, Victoria. Anaphylaxis notifications linked to unapproved peptides. Health advisory 261027, 27 Oct 2026; read 18 Nov 2026. www.health.vic.gov.au/health-advisories/anaphylaxis-notifica…
  4. Therapeutic Goods Administration. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Safety advisory, 13 Apr 2026; read on the Internet Archive capture of 10 Aug 2026, the newest capture, because tga.gov.au did not respond on 18 Nov 2026. www.tga.gov.au/safety/safety-monitoring-and-information/safe…
  5. Hsieh MJ, Liu HT, Wang CN, et al. [Cell, chick-embryo and rat study of BPC-157, new blood-vessel growth and the VEGFR2 receptor]. J Mol Med (Berl), 2017;95(3):323–333. PMID 27847966. pubmed.ncbi.nlm.nih.gov/27847966/
  6. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. [Literature and patent review of BPC-157, including its possible adverse consequences]. Pharmaceuticals (Basel), 2025;18(2):185. PMID 40005999 (full text read 18 Nov 2026). pmc.ncbi.nlm.nih.gov/articles/PMC11859134/
  7. Sikiric P, Seiwerth S, Skrtic A, et al. [Comment on Józwiak et al. 2025, disputing the angiogenesis concern]. Pharmaceuticals (Basel), 2025;18(10):1450. PMID 41155565. pubmed.ncbi.nlm.nih.gov/41155565/
  8. Moiz A, O’Keefe EL, O’Keefe JH. Dangers of injectable peptides and other unregulated “biohacking” drugs. Mo Med, 2026;123(4):337–343. PMID 42757290 (full text read 18 Nov 2026). pmc.ncbi.nlm.nih.gov/articles/PMC13585006/
  9. Tham A, Hodgkins CW, Kennedy JG. Investigational peptides in orthopaedic practice: evidence, safety, and patient counseling for BPC-157, thymosin beta-4, and TB-500. J Am Acad Orthop Surg, 2026 (online ahead of print). PMID 42937313. pubmed.ncbi.nlm.nih.gov/42937313/
  10. PubMed searches run 18 Nov 2026: BPC-157 with cancer, tumour, carcinogen or neoplasm terms (no human study or case report linking it to cancer), and with purity, counterfeit, seized, contamination or product terms (no independent quality survey). Database searches. pubmed.ncbi.nlm.nih.gov/?term=%28BPC-157%5Btiab%5D+OR+%22BPC…

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

What are the side effects of BPC-157?

Nobody has characterised them. In a July 2026 briefing, FDA staff found five small, short human studies with limited safety data and concluded there is insufficient clinical safety information to characterise BPC-157’s safety profile. Of three adverse-event reports, they judged one, with a product that also contained TB-500, “likely due to the drug product”, and wrote that it is unclear whether the three were attributable to BPC-157.

What is known about BPC-157 and cancer?

There are no human data either way. FDA identified no carcinogenicity study; cell and rodent studies report new blood-vessel growth, which some reviewers flag as a theoretical tumour concern and researchers at the University of Zagreb dispute.

What adverse events have been reported for BPC-157?

FDA’s database held three reports to December 2025: injection-site redness and swelling, shortness of breath, and skin and gum darkening with a product that also contained TB-500. FDA judged the last “likely due to the drug product” but, because the product contained two peptides, could not assess whether BPC-157 played a role. Of all three, it wrote that attribution to BPC-157 is unclear.

What does FDA say about immune reactions to BPC-157?

FDA staff wrote in 2026 that, given by injection or nasally, BPC-157 “may pose a significant risk for immunogenicity”, potentially amplified by aggregation and impurities, and they found no study that formally investigated it. Australia’s TGA has received reports of severe allergic reactions to unapproved peptide products without saying which, and Victoria’s 2026 advisory on 13 anaphylaxis cases names no substance.

How do I report a reaction to a peptide?

Seek medical care first. Then report it to FDA MedWatch in the US, the MHRA Yellow Card scheme in the UK or the TGA in Australia; our reporting page explains each route.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page